Unveiling the Multifaceted Roles of ISG15: From Immunomodulation to Therapeutic Frontiers.
IFN
ISG15
ISGylation
adjuvant
cytokines
immunity
inflammation
vaccines
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
01 Feb 2024
01 Feb 2024
Historique:
received:
22
12
2023
revised:
24
01
2024
accepted:
30
01
2024
medline:
24
2
2024
pubmed:
24
2
2024
entrez:
24
2
2024
Statut:
epublish
Résumé
The Interferon Stimulated Gene 15 (ISG15), a unique Ubiquitin-like (Ubl) modifier exclusive to vertebrates, plays a crucial role in the immune system. Primarily induced by interferon (IFN) type I, ISG15 functions through diverse mechanisms: (i) covalent protein modification (ISGylation); (ii) non-covalent intracellular action; and (iii) exerting extracellular cytokine activity. These various roles highlight its versatility in influencing numerous cellular pathways, encompassing DNA damage response, autophagy, antiviral response, and cancer-related processes, among others. The well-established antiviral effects of ISGylation contrast with its intriguing dual role in cancer, exhibiting both suppressive and promoting effects depending on the tumour type. The multifaceted functions of ISG15 extend beyond intracellular processes to extracellular cytokine signalling, influencing immune response, chemotaxis, and anti-tumour effects. Moreover, ISG15 emerges as a promising adjuvant in vaccine development, enhancing immune responses against viral antigens and demonstrating efficacy in cancer models. As a therapeutic target in cancer treatment, ISG15 exhibits a double-edged nature, promoting or suppressing oncogenesis depending on the tumour context. This review aims to contribute to future studies exploring the role of ISG15 in immune modulation and cancer therapy, potentially paving the way for the development of novel therapeutic interventions, vaccine development, and precision medicine.
Identifiants
pubmed: 38400136
pii: vaccines12020153
doi: 10.3390/vaccines12020153
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Spanish Ministry of Science and Innovation (MCIN) / Spanish State Research Agency, state secretary of R+D and FEDER/FSE
ID : SAF2017-88089-R and PDC2021-121307-I00 to SG and ME, PID2020-117425RB-C21 to SG and PID2020-117425RB-C22 to CEG.